A new index of priority symptoms in advanced ovarian cancer

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 214-219

  Jensen, Sally E ^a   Rosenbloom, Sarah K ^b   Beaumont, Jennifer L ^b   Abernethy, Amy ^c   Jacobsen, Paul B ^d   Syrjala, Karen ^e   Cella, David ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Ovarian Cancer; Quality of life; Symptom Index

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; FATIGUE; FEMALE; HAIR LOSS; HUMAN; INTERNAL CONSISTENCY; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NCCN FACT OVARIAN SYMPTOM INDEX 18; NEUROPATHY; OVARY CANCER; PAIN; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SLEEP DISORDER; SWELLING; VOMITING; WELLBEING;

ACTIVITIES OF DAILY LIVING; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79251601350     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.09.025     Document Type: Article

References (28)

1. American Cancer Society Cancer Facts & Figures 2008 2008 American Cancer Society Atlanta
2. J.L. Benedet, H. Bender, H. Jones, H.Y. Ngan, and S. Pecorelli FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 2 2000 Aug 209 262
3. L. Wenzel, H.Q. Huang, B. Monk, P.G. Rose, and D. Cella Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 23 24 2005 Aug 5605 5612
4. S.K. Steginga, and J. Dunn Women's experiences following treatment for gynecologic cancer Oncol Nurs Forum 24 8 1997 Sept 1403 1408
5. D.C. Bodurka, and C.C. Sun Sexual function after gynecologic cancer Obstet Gynecol Clin North Am 33 4 2006 Dec 621 630
6. K.M. Taylor, K.G. Macdonald, A. Bezjak, P. Ng, and A.D. DePetrillo Physicians' perspective on quality of life: an exploratory study of oncologists Qual Life Res 5 1 1996 Feb 5 14
7. E.A. Rothermich, and D.S. Pathak References for health-related quality-of-life claims in prescription drug advertisements Am J Health Syst Pham 54 22 1997 Nov 2596 2599
8. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) Quality of Life Subcommittee Meeting Transcript, February 10, 2000.
9. S.X. Kong, and S.K. Gandhi Methodologic assessments of quality of life measures in clinical trials Ann Pharmacother 31 7-8 1997 Jul-Aug 830 836
10. K. Basen-Enquist, D. Bodurka-Bevers, M.A. Fitzgerald, K. Webster, D. Cella, and S. Hu Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) J Clin Oncol 19 6 2001 Mar 1809 1817
11. D. Cella, D. Paul, S. Yount, R. Winn, C.H. Chang, and D. Banik What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN) Cancer Invest 21 4 2003 526 535
12. C. Brunelli, M. Costantini, P. DiGiulio, M. Gallucci, F. Fusco, and G. Miccinesi Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree? J Pain Symptom Manage 15 3 1998 Mar 151 158
13. A.C. Justice, L. Rabeneck, R.D. Hays, A.W. Wu, and S.A. Bozzette Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group J Acquir Immune Defic Syndr 21 2 1999 June 126 133
14. C.L. Nekolaichuk, E. Bruera, K. Spachynski, T. MacEachern, J. Hanson, and T.O. Maguire A comparison of patient and proxy symptom assessments in advanced cancer patients Palliat Med 13 4 1999 July 311 323
15. R.J. Stephens, P. Hopwood, D.J. Girling, and D. Machin Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self ratings? Qual Life Res 6 3 1997 Apr 225 236
16. A.S. Stromgren, M. Groenvold, A. Sorensen, and L. Andersen Symptom recognition in advanced cancer. A comparison of nursing records against patient self-rating Acta Anaesthesiol Scand 45 9 2001 Oct 1080 1085
17. Cella D, Rosenbloom SK, Beaumont JL, Yount SE, Paul D, Hampton D et al. Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer. [Submitted].
18. D.F. Cella, D.S. Tulsky, G. Gray, B. Sarafian, S. Lloyd, and E. Linn The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure J Clin Oncol 11 3 1993 Mar 570 579
19. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
20. D.L. Fairclough, and D.F. Cella Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions Qual Life Res 5 3 1996 321 329
21. H.S. Donovan, E.M. Hartenbach, and M.W. Method Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer Gynecol Oncol 99 2 2005 Nov 404 411
22. M. Hofman, J.L. Ryan, C.D. Figueroa-Moseley, P. Jean-Pierre, and G.R. Morrow Cancer-related fatigue: the scale of the problem Oncologist 12 Supplement 1 2007 S4 S10
23. K. Houck, N.E. Avis, J.M. Gallant, A.F. Fuller, and A. Goodman Quality of life in advanced ovarian cancer: identifying specific concerns J Palliat Med 2 4 1999 397 402
24. A. Luciani, P. Jacobsen, M. Extermann, P. Foa, D. Marussi, and J.A. Overcash Fatigue and functional dependence in older cancer patients Am J Clin Oncol 31 5 2008 Oct 424 430
25. E.A. Calhoun, E.E. Welshman, C.H. Chang, J.R. Lurain, D.A. Fishman, and T.L. Hunt Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx ) questionnaire for patients receiving systemic chemotherapy Int J Gynecol Cancer 13 6 2003 Nov-Dec 741 748
26. H.Q. Huang, M.F. Brady, D. Cella, and G. Fleming Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study Int J Gynecol Cancer 17 2 2007 Mar-April 387 393
27. K.L. Mirabeau-Beale, A.B. Kornblith, R.T. Penson, H. Lee, A. Goodman, and S.M. Campos Comparison of the quality of life of early and advanced stage ovarian cancer survivors Gynecol Oncol 114 2 2009 Aug 353 359
28. C.L. Carmack Taylor, K. BAsen-Engquist, E.H. Shinn, and D.C. Bodurka Predictors of sexual functioning in ovarian cancer patients J Clin Oncol 22 5 2004 Mar 881 889